Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivipansel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE known ✓ | P16581 | 19/20 | 0.83 |
| ▸ | SELP known ✓ | P16109 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216731 | 0.95 | SELE (0.76) | SELESELP | |
| SCHEMBL15214250 | 0.94 | SELE (0.74) | SELESELP | |
| SCHEMBL25562916 | 0.94 | SELE (0.73) | SELE | |
| SCHEMBL12239982 | 0.93 | SELE (0.72) | SELE | |
| SCHEMBL15160862 | 0.93 | SELE (0.70) | SELESELP | |
| SCHEMBL14667944 | 0.93 | SELE (0.71) | SELE | |
| SCHEMBL2742900 | 0.92 | SELE (0.71) | SELESELP | |
| SCHEMBL12419366 | 0.92 | SELE (0.70) | SELESELP | |
| SCHEMBL12216742 | 0.91 | SELE (0.70) | SELESELP | |
| SCHEMBL13948336 | 0.91 | SELE (0.70) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021257398-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | MAGNANI JOHN L (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS INC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8895510-B2 | Pan-selectin inhibitor with enhanced pharmacokinetic activity | GLYCOMIMETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GLYCOMIMETICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-8518896-B2 | Treatment of cancers of the blood using selected glycomimetic compounds | GLYCOMIMETICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1934236-B1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2009011889-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | GLYCOMIMETICS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | SELE 1/4885SELP 4/4885 |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | SELPLG, SELP, SELE | SELE 3/4885SELP 2/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GAP43, PYGB, NLN | SELE 1302/4885SELP 640/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | SELE 2/4885SELP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.